Questions about Fulcrum Phase 2 Clinical Trials for FSHD
August of this year Fulcrum Therapeutics launched ReDUX4, a phase 2 clinical trial for people with facioscapulohumeral muscular dystrophy (FSHD). This is testing the safety and efficacy of a repurposed drug called losmapimod. The ReDUX4 trial has sites in the US, Canada, Germany, Spain, and France.
Have you read the article on the MD News Columns page? Are you excited about the possibilities of a treatment? Did you participate in this study, what was it like? Share your experience with us!
Sorry, there were no replies found.
Log in to reply.